Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single gene therapy injection hold back wet AMD for years?

NCT ID NCT06346600

Disease control Sponsor: Skyline Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This study follows people with wet age-related macular degeneration who received an injection of SKG0106, an experimental gene therapy, in an earlier trial. Researchers will track their eye health, vision, and any side effects for up to 5 years after the injection. The goal is to see whether the treatment's effects last and remain safe over the long term.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SKG0106, an investigational gene therapy given as an injection into the eye
What this could lead to
If this follow-up shows lasting safety and stable vision, it could support SKG0106 as a longer-lasting treatment for wet age-related macular degeneration, reducing the need for frequent eye injections.
What could go wrong
This is an observational follow-up, not a controlled trial, so it cannot prove the treatment works. The number of participants is small, and long-term side effects or loss of vision benefit may still appear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 83 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Mar 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

It is expected that a total of 83 study subjects from parent study will be enrolled. Subjects who meet all the inclusion criteria and for whom none of the exclusion criteria apply will be eligible for enrollment.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects who only meet all of the following criteria are eligible for this study: * nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection; * Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study Exclusion Criteria: * Subjects who are judged by the investigator unsuitable for this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neovascular (WET) age-related macular degeneration are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neovascular (WET) age-related macular degeneration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Hospital

    NOT_YET_RECRUITING

    Beijing, China

  • EYE & ENT Hospital of Fudan University

    RECRUITING

    Shanghai, China

  • Eye Hospital, WMU (Zhejiang Eye Hospital)

    NOT_YET_RECRUITING

    Wenzhou, Zhejiang, China

  • Ophthalmic Consultants of Boston

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, China

  • Retina Consultants of Texas

    NOT_YET_RECRUITING

    Katy, Texas, 77494, United States

  • The Second Hospital Of Anhui Medical University

    NOT_YET_RECRUITING

    Hefei, Anhui, China

  • Wagner Macula & Retina Center

    NOT_YET_RECRUITING

    Norfolk, Virginia, 23502, United States

  • Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine

    NOT_YET_RECRUITING

    Shanghai, China

  • Zhejiang Provincial People's Hospital

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.